TINA FLATAU

Managing Director, MedAnnex & OncoBioPharm

Tina has worked in biopharmaceutical R&D for over 25 years. A Principal in PwC’s Pharmaceutical Industry Group, for the past 20 years she has been a manager/ advisor for pharmas and start-ups in biologics. Tina ran R&D Operations at RNA modulation company Prosensa Therapeutics (NASDAQ: [RNA] 2013), a rare disease developer spun out from Leiden University with funds from patient groups, non-dilutive grants, individual and corporate investors, as well as big pharma.

Tina regards mixed models of early development funding as the new ‘normal’, relationships with strategic partners in academia, industry and patient organisations are all core to success.

Since 2016 Tina has been working with Edinburgh-based MedAnnex Ltd working in annexin-A1 modulation. Tina is also Chair of the rare disease patient organisation Action Duchenne Ltd.

 LIVE ONLINE

16 November 2020

BOOK YOUR PLACE NOW

 LIVE ONLINE

17 November 2020

BOOK YOUR PLACE NOW